Postop Pain Management in Pituitary Tumour Patients
Sponsored by Hamilton Health Sciences Corporation
About this trial
Last updated 8 months ago
Study ID
17065
Status
RecruitingType
Interventional
Phase
Phase 4
Placebo
Yes
Accepting
18 to 100 Years
All Sexes
Not accepting
Healthy Volunteers
Trial Timing
Started Nov 2024
What is this trial about?
To assess the benefit of using an additional nerve block during minimally invasive pituitary surgery, to improve pain management after surgery. The medication (Bupivacaine) or a placebo (saline) will be injected during surgery and patients will be asked about their level of pain at multiple time points in the first 24 hours following surgery. Some patients will be randomized to a third, sham group that do not receive any additional injection. The aim is to improve patient outcomes and reduce the need for pain medication after surgery.
What are the participation requirements?
Inclusion Criteria
* adult patients (18 yrs or older)
* undergoing endonasal pituitary adenoma resection
Exclusion Criteria
* Patients with pre-existing chronic pain conditions requiring antidepressants (serotonin reuptake inhibitors), benzodiazepines, gabapentin, or opioid drugs
* contraindications to the performance of SPGB such as known allergy to used medications
* chronic alcohol abuse
* uncontrolled systemic arterial hypertension
* severe kidney or liver diseases
* cardiomyopathies or sustained cardiac arrhythmias (permanent paroxystic atrial fibrillation or other sustained supraventricular rhythmic anomalies)